NCT02641262

Brief Summary

ST-segment elevation myocardial infarction (STEMI) remains among the most acute and critical diseases, with primary percutaneous coronary intervention (pPCI) and thrombolysis as mainstay reperfusion treatments. Real-world implementation of current guidelines for STEMI management has been assessed in developed countries and large Chinese cities. However, until now, there has been no registry on patients with STEMI in Henan, the most populated (about 100 million) and predominantly rural (66%) province in central China. This registry is aimed to assess management practices, time delays, outcomes and reasons for not receiving reperfusion therapy in consecutive STEMI patients in reperfusion-capable hospitals, i.e., tertiary and secondary, in Henan province.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
5,479

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Sep 2016

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 15, 2015

Completed
14 days until next milestone

First Posted

Study publicly available on registry

December 29, 2015

Completed
8 months until next milestone

Study Start

First participant enrolled

September 1, 2016

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2018

Completed
1.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2019

Completed
Last Updated

August 5, 2022

Status Verified

August 1, 2022

Enrollment Period

1.9 years

First QC Date

December 15, 2015

Last Update Submit

August 3, 2022

Conditions

ST-segment Elevation Myocardial Infarction

Keywords

Myocardial InfarctionAngioplasty, Balloon, CoronaryDrug Therapy

Outcome Measures

Primary Outcomes (1)

  • All causes mortality

    At discharge, an average of 10 days

Secondary Outcomes (4)

  • All causes mortality

    30 days

  • adverse cardiovascular and cerebrovascular events (MACCE, death, congestive heart failure, reinfarction and ischemic stroke)

    At discharge, an average of 10 days

  • All causes mortality

    6 months

  • All causes mortality

    1 year

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

STEMI patients within 30 days of symptom onset

You may qualify if:

  • STEMI is defined in accordance with the universal definition of myocardial infarction, specifically as persistent ST-segment elevation (≥0.1 millivolt at J points) in 2 or more contiguous leads.

You may not qualify if:

  • percutaneous coronary intervention (PCI)-related myocardial infarction or coronary artery bypass graft (CABG)-related myocardial infarction.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Zhengzhou university People's Hospital

Zhengzhou, Henan, 450000, China

Location

Related Publications (4)

  • Wang S, Zhang Y, Yang W, Wang X, Zhu Z, Qi D, Zhang J, Zhang J, Gao C. Impact of stress hyperglycemia ratio on incidence of in-hospital cardiogenic shock in patients with ST-elevation myocardial infarction: a prospective, multicenter study. Front Endocrinol (Lausanne). 2025 Dec 12;16:1677084. doi: 10.3389/fendo.2025.1677084. eCollection 2025.

    PMID: 41458546DERIVED

  • Wang S, Zhang Y, Qi D, Wang X, Zhu Z, Yang W, Li M, Hu D, Gao C. Development and validation of a risk score for predicting 30-day mortality in patients with ST elevation myocardial infarction. Sci Rep. 2025 Mar 15;15(1):8930. doi: 10.1038/s41598-025-92615-3.

    PMID: 40087520DERIVED

  • Zhang Y, Wang S, Cheng Q, Zhang J, Qi D, Wang X, Zhu Z, Li M, Hu D, Gao C; Henan STEMI registry Study Group. Reperfusion strategy and in-hospital outcomes for ST elevation myocardial infarction in secondary and tertiary hospitals in predominantly rural central China: a multicentre, prospective and observational study. BMJ Open. 2021 Dec 20;11(12):e053510. doi: 10.1136/bmjopen-2021-053510.

    PMID: 34930741DERIVED

  • Zhang Y, Wang S, Yang S, Yin S, Cheng Q, Li M, Qi D, Wang X, Zhu Z, Zhao L, Hu D, Gao C. Rationale and design of the Henan ST elevation myocardial infarction (STEMI) registry: a regional STEMI project in predominantly rural central China. BMC Cardiovasc Disord. 2019 Nov 28;19(1):271. doi: 10.1186/s12872-019-1250-9.

    PMID: 31783791DERIVED

MeSH Terms

Conditions

ST Elevation Myocardial InfarctionMyocardial Infarction

Condition Hierarchy (Ancestors)

Myocardial IschemiaHeart DiseasesCardiovascular DiseasesVascular DiseasesInfarctionIschemiaPathologic ProcessesPathological Conditions, Signs and SymptomsNecrosis

Study Officials

  • Chuanyu Gao, MD

    Henan Institute of Cardiovascular Epidemiology

    PRINCIPAL INVESTIGATOR

  • Dayi Hu, MD

    Henan Institute of Cardiovascular Epidemiology

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
1 Year
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director

Study Record Dates

First Submitted

December 15, 2015

First Posted

December 29, 2015

Study Start

September 1, 2016

Primary Completion

August 1, 2018

Study Completion

September 1, 2019

Last Updated

August 5, 2022

Record last verified: 2022-08

Locations

CN(1)